Psychopharmacology

, Volume 97, Issue 1, pp 1–11 | Cite as

Neuroleptic-induced akathisia: a review

  • Lenard A. Adler
  • Burt Angrist
  • Stewart Reiter
  • John Rotrosen
Review

Abstract

Neuroleptic-induced akathisia (NIA) is a relatively common side effect of neuroleptics, in which patients complain of a subjective sense of restlessness usually referable to the legs and have characteristic motor movements. This paper will review: 1) history of spontaneously occurring syndromes of pathologic restlessness and NIA, 2) the clinical significance of NIA, 3) issues concerning the diagnosis and quantification of NIA, 4) treatments of NIA and 5) possible future directions for research in this area. Special attention will be paid to newer treatments for this syndrome, specifically beta-blockers.

Key words

Akathisia Neuroleptics Beta-blockers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adler L, Angrist B, Peselow E, Corwin J, Rotrosen J (1985) Efficacy of propranolol in neuroleptic-induced akathesia. J Clin Psychopharmacol 5:164–166Google Scholar
  2. Adler L, Angrist B, Peselow E, Corwin J, Maslansky R, Rotrosen J (1986) A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 149:42–45Google Scholar
  3. Adler L, Angrist B, Peselow E, Reitano J, Rotrosen J (1987a) Clonidine in neuroleptic-induced akathisia. Am J Psychiatry 144:235–236Google Scholar
  4. Adler LA, Reiter S, Corwin J, Hemdal P, Angrist B, Rotrosen J (1987b) Differential effects of benztropine and propranolol in akathisia. Psychopharmacol Bull 23:519–521Google Scholar
  5. Adler LA, Reiter S, Angrist B, Rotrosen J (1987c) Pindolol and propranolol in neuroleptic-induced akathisia. Am J Psychiatry 144:1241–1242Google Scholar
  6. Ayd FJ (1960) Drug-induced extrapyramidal reactions: their clinical manifestations and treatment with akineton. Psychosomatics 1:143–150Google Scholar
  7. Ayd FJ (1961) A survery of drug-induced extrapyramidal reactions. JAMA 175:1054–1060Google Scholar
  8. Barnes TRE, Braude WM (1985) Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 42:874–878Google Scholar
  9. Barnes TRE, Braude WM (1986) Toward a more reliable diagnosis of akathisia (in reply). Arch Gen Psychiatry 43:1016Google Scholar
  10. Bartels M, Heide K, Mann K, Schied (1987) Treatment of akathisia with lorazepam: an open trial. Pharnacopsychiatry 20:51–53Google Scholar
  11. Beard GM (1880) A practical treatise on nervous exhaustion, 2nd edn. Wood, New York, pp 41–42Google Scholar
  12. Bing R (1919) A textbook of nervous diseases. (Allen CL trans) Rebman Company. New York, p 412Google Scholar
  13. Bing R (1923) Über einige bemerkenswerte Begleiterscheinungen der exrapyramidalen Rigidität (Akathesie — Mikrographie —Kinesia paradoxica). Schweiz Med Wochenschr 53:167–171Google Scholar
  14. Blom S, Ekbom KA (1961) Comparison between akathisia developing on treatment with phenothiazine derivative and the restless leg syndrome. Acta Med Scand 170:689–694Google Scholar
  15. Braude WM, Barnes TRE (1983) Late onset akathisia — an indicant of covert dyskinesia: two case reports. Am J Psychiatry 140:611–612Google Scholar
  16. Braude WM, Barnes TRE, Gore SM (1983) Clinical characteristics of akathisia. Br J Psychiatry 143:134–150Google Scholar
  17. Brown KW, Glen SE, White T (1987) Low serum iron status and akathisia. Lancet I:1234–1236Google Scholar
  18. Charney DS, Sternber DE, Kleber HD, Henninger GR, Redmond DE (1981) The clinical use of clonidine in abrupt withdrawal from methadone. Arch Gen Psychiatry 38:1273–1277Google Scholar
  19. Chouinard G, Annable L, Ross-Chouinard A, Nestoros JN (1979) Factors related to tardive dyskinesia. Am J Psychiatry 136:79–83Google Scholar
  20. Chouinard G, Ross-Chouinard A, Annable L, Jones BD (1980) Extrapyramidal rating scale. Can J Neurol Sci 7:233Google Scholar
  21. Crane GE (1972) Pseudoparkinsonism and tardive dyskinesia. Arch Neurol 27:426–430Google Scholar
  22. Cruickshank DM (1980) The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J 100:160–178Google Scholar
  23. Delay J, Deniker P, Green A, Mordret M (1957) Le syndrome exitomoteur provoque pat les medicaments neuroleptiques. Press Med 65:1771–1774Google Scholar
  24. Derom E, Elinck W, Buylaert W, Van der Straeten M (1984) Which beta-blocker for the restless leg? Lancet I:857Google Scholar
  25. DiMascio A, Bernardo DL, Greenblatt D, Marder JE (1976) A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 33:559–602Google Scholar
  26. Donlon P (1973) The therapeutic use of diazepam for akathisia. Psychosomatics 14:222–225Google Scholar
  27. Drachman DA (1977) Central cholinergic system and memory. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 28–233Google Scholar
  28. Drake RE, Ehrlich J (1985) Suicide attempts associated with akathisia. Am J Psychiatry 142:499–501Google Scholar
  29. Dupuis B, Catteau J, Dumon J-P, Libert C, Petit H (1987) Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 144:802–805Google Scholar
  30. Ekbom KA (1944) Astehnia Crurum Paraesthetica (“Irritable legs”). Acta Med Scand 118:197–209Google Scholar
  31. Ekbom KA (1960) Restless leg syndrome. Neurology 10:868–873Google Scholar
  32. Freyhan FA (1957) Psychomotility and parkinsonism in treatment with neuroleptic drugs. Arch Neurol Psychiatry 78:465–472Google Scholar
  33. Friis T, Christensen TR, Gerlach J (1982) Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia: a double-blind cross-over study with placebo. Acta Psychiatr Scand 67:178–187Google Scholar
  34. Frishman WM, Sonnenblick EH (1986) Beta-adrenergic blocking drugs. In: Hurst JW, Logue RB, Rackley CE, Sonnenblick EH, Wallace AG, Wenger NK (eds) The heart, 6th edn, McGrawhill, New York, pp 1606–1621Google Scholar
  35. Gagrat D, Hamilton J, Belmatier R (1978) Intravenous diazepam in the treatment of neuroleptic-induced dystonia or akathisia. Am J Psychiatry 135:1232–1233Google Scholar
  36. Gold MS, Redmond DE, Kleiber HD (1978) Clonidine blocks the acute opiate withdrawal syndrome. Lancet II:403–405Google Scholar
  37. Greendyke RM, Kanter DR (1987) Plasma propranolol levels and their effect on thioridazine and haloperidol concentrations. J Clin Psychopharmacology 7:178–182Google Scholar
  38. Guidicelli JF, Richer C, Ganansia J, Warrington S, Abriol C, Rulliere R (1983) Betaxolol: β-Adrenoceptor blocking effects and phamacolinetics in man. In: Morselli PL, Kilborn JR, Cavero I, Harrison DC, Langer SZ (eds) Betaxolol and other β-adrenoceptor antagonists. Raven Press, New York, pp 89–99Google Scholar
  39. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55Google Scholar
  40. Haskovec L (1903) Nouvelles remarques sur l'akathisie. Nouv Iconograph Salpetrière 16:287–296Google Scholar
  41. Jeste DV, Wyatt RJ (1982) Understanding and treating tardive dyskinesia. The Guilford Press, New York London, p 64Google Scholar
  42. Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B (1982) A prospecitive study of tardive dyskinesia development: preliminary results. J Clin Psychopharmacology 2:345–349Google Scholar
  43. Keckich WA (1978) Violence as a manifestation of akathisia. JAMA 240:2185Google Scholar
  44. Kendler (1976) A medical student's experience with akathisia. Am J Psychiatry 133:454–455Google Scholar
  45. Koch-Weser J (1979) Metroprolol. New Engl J Med 301:698–703Google Scholar
  46. Kruse W (1960) Treatment of drug-induced extrapyramidal symptoms. Dis Nerv Syst 21:79–81Google Scholar
  47. Kulik AV, Wilbur R (1983) Case report of propranolol (Inderal) pharmacotherapy for neuroleptic-induced akathisia and tremor. Prog Neuropsychopharmacol Biol Psychiatry 7:223–225Google Scholar
  48. Kutcher SP, Mackenzie S, Galarraga, Szalai J (1987) Clonazepam treatment of adolescents with neuroleptic-induced akathisia. Am J Psychiatry 144:823–824Google Scholar
  49. Langer SZ (1977) Presynaptic receptors and their role in the regulation of transmitter release. Br J Pharmacol 60:481–497Google Scholar
  50. Lipinski JF, Zubenko GS, Barriera P, Cohem BM (1983) Propranolol in the treatment of neuroleptic-induced akathisia. Lancet II:685–686Google Scholar
  51. Lipinski JF, Zubenko GS, Cohen BM, Barriera PJ (1984) Propranolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 141:412–415Google Scholar
  52. Marsden CD, Jenner P (1980) The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 10:55–72Google Scholar
  53. Merrick EM, Schmitt PP (1973) A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel). Curr Ther Res 15:552–558Google Scholar
  54. Munetz MR (1986) Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 43:1015Google Scholar
  55. Munetz MR, Cornes CL (1982) Distinguishing akathisia and tardive dyskinesia: A review of the literature. J Clin Psychopharmacol 3:343–350Google Scholar
  56. Neu C, DiMascio A, Demirgian E (1972) Antiparkinsonian medication in the treatment of extrapyramidal side-effects: single or multiple doses? Curr Ther Res 4:246–251Google Scholar
  57. Patterson JF (1986) Pseudoakathisia associated with atenolol. J Clin Psychopharmacol 6:390Google Scholar
  58. Ratey JJ, Sorgi P, Polakoff S (1985) Nadolol as a treatment for akathisia. Am J Psychiatry 142:640–642Google Scholar
  59. Reiter S, Adler L, Angrist B, Corwin J, Rotrosen J (1987a) Atenolol and propranolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 7:279–280Google Scholar
  60. Reiter S, Adler L, Erle S, Duncan E (1987b) Neuroleptic-induced akathisia treated with pindolol. Am J Psychiatry 144:383–384Google Scholar
  61. Roehrich H, Gold MS (1987) Propranolol as adjunct to clonidine in opiate detoxification. Am J Psychiatry 144:1099–1100Google Scholar
  62. Shaw ED, Mann JJ, Widen P, Sinscheimer LM, Brunn RD (1986) A case of suicidal and homicidal ideation and akathisia in a double-blind neuroleptic crossover study. J Clin Psychopharmacol 6:196–197Google Scholar
  63. Shear K, Frances A, Weiden P (1983) Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol 3:235–236Google Scholar
  64. Silver JM, Yudofsky SC, Kogan M, Katz BI (1986) Elevation of thioridazine plasma levels by propranolol. Am J Psychiatry 143:1290–1292Google Scholar
  65. Simpson GM (1977) Neurotoxicity of major tranquilizers. In: Roizin L, Shiroki H, Grcevic N (eds) Neurotoxicology. Raven Press. New York, p 3Google Scholar
  66. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side-effects. Acta Psychiatry Scand [Suppl] 212:11–19Google Scholar
  67. Stahl SM (1985) Akathisia and tardive dyskinesia: changing concepts. Arch Gen Psychiatry 42:915–917Google Scholar
  68. Stenson RL, Donlon PT, Meyer JE (1976) Comparison of benztropine mesylate and amantdine HCl in neuroleptic-induced extrapyramidal symptoms. Compr Psychiatry 17:763–768Google Scholar
  69. Strang RR (1967) The symptom of restless legs. Med J Austr 24:1211–1213Google Scholar
  70. Trzepacz P, Violette EJ, Sateia MJ (1984) Opiates and restless legs. Am J Psychiatry 141:993–995Google Scholar
  71. Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs. Arch Gen Psychiatry 31:67–72Google Scholar
  72. Van Putten T (1975) The many faces of akathisia. Compr Psychiatry 16:43–47Google Scholar
  73. Van Putten T, Marder SR (1987) Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry [Suppl 9] 48:13–19Google Scholar
  74. Van Putten T, Mutalipassi LR, Malkin SR (1974) Phenothiazine induced decompensation. Arch Gen Psychiatry 30:102–105Google Scholar
  75. Van Putten T, May PRA, Marder SR (1984) Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 41:1036–1039Google Scholar
  76. Washton AM, Resnick RB (1981) Clonidine in opiate withdrawal: review and appraisal of clinical findings. Pharmacotherapy 1:140–146Google Scholar
  77. Weiden P (1985) Akathisia from prochlorperazine. JAMA 253:635Google Scholar
  78. Willis T (1985) The London practice of physic, 1st edn. Bassett and Crooke. London, p 404Google Scholar
  79. Wilson SA, Kinnier (1940) In: Bruce AN (ed) Neurology, vols 1 and 2. A William Wood book. Williams and Wilkins. Baltimore, p 118, (vol 1) and p 793 (vol 2)Google Scholar
  80. Wilcox JA, Tsuang J (1987) Amantadine and psychosis. Presented at the 42nd Annual Meeting of the Society of Biological Psychiatry, Chicago, Illinois, May 6–10Google Scholar
  81. Zubenko GS, Cohen BM, Lipinski JF, Jonas JM (1984a) Use of clonidine in the treatment of akathisia. Psychiatr Res 13:253–259Google Scholar
  82. Zubenko GS, Garreira P, Lipinski JF (1984b) Development of tolerance to the therapeutic effect of amantadine on akathisia. J Clin Psychopharmacol 4:218–219Google Scholar
  83. Zubenko GS, Lipinski JF, Cohen BM, Barriera PJ (1984c) Comparison of metoprolol and propranolol in the treatment of akathisia. Psychiatr Res 11:143–148Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Lenard A. Adler
    • 1
  • Burt Angrist
    • 1
  • Stewart Reiter
    • 1
  • John Rotrosen
    • 1
  1. 1.Psychiatry Service, New York VAMC and Department of PsychiatryNew York University School of MedicineNew YorkUSA

Personalised recommendations